All In Biotech

Drug Trial Radar · NCT05005338

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

An Open Label Phase 1 Study to Determine the Absolute Bioavailability of Single and Repeated Daily Oral Administration of BIIB122 (DNL151) Utilizing a Microtracer Dose of Intravenously Administered [14C] BIIB122 ([14C] DNL151) to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jul 28, 2021

Primary completion

Sep 23, 2021

Study completion Sep 23, 2021

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Denali Therapeutics Inc.
First posted
Aug 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive days of oral dosing, approximating steady state.

Conditions

  • Healthy Volunteers

Interventions

  • BIIB122 (DNL151)Drug

    Oral doses

  • [14C] BIIB122 ([14C] DNL151)Drug

    Intravenous doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK Parameter: The first time to maximum observed concentration (Tmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 1 day
  2. PK Parameter: Maximum observed concentration (Cmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 1 day
  3. PK Parameter: Area under the concentration-time curve (AUC) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151 in plasma following oral and intravenous administrationTime frame: 1 day
  4. PK Parameter: Time from baseline at which half of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151 has been eliminated (t1/2) in plasma after oral and intravenous administrationTime frame: 1 day
  5. PK Parameter: Clearance (CL/F and CL) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 1 day
  6. PK Parameter: Volume of distribution (Vd/F and Vd) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 1 day
  7. PK Parameter: Absolute bioavailability (F) of BIIB122 (DNL151) after oral administrationTime frame: 1 day
  8. PK Parameter: The first time to maximum observed concentration (Tmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 21 days
  9. PK Parameter: Maximum observed concentration (Cmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 21 days
  10. PK Parameter: Concentration of BIIB122 (DNL151) in plasma at the end of dosing intervalTime frame: 21 days
  11. PK Parameter: Area under the concentration-time curve of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) in plasma following oral and intravenous administrationTime frame: 21 days
  12. PK Parameter: Time from baseline at which half of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) has been eliminated (t1/2) in plasma after oral and intravenous administrationTime frame: 21 days
  13. PK Parameter: Volume of distribution (Vd/F and Vd) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 21 days
  14. PK Parameter: Clearance (CL/F and CL) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 21 days
  15. PK Parameter: Absolute bioavailability (F) of BIIB122 (DNL151) after oral administrationTime frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.